Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.02. | Relmada acquires Tourette's therapy rights from Asarina | 5 | Pharmaceutical Technology | ||
06.02. | Relmada Therapeutics acquires potential therapy for Tourette Syndrome from Asarina Pharma | 2 | Seeking Alpha | ||
04.10.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 04.10.2024 | 764 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 04.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 04.10.2024ISIN NameCA2265331074 CREW... ► Artikel lesen | |
02.10.24 | XFRA APS: AUSSETZUNG/SUSPENSION | 318 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILASARINA PHARMA AB... ► Artikel lesen | |
16.09.24 | Nasdaq Stockholm AB: Delisting of Asarina Pharma AB (publ) from Nasdaq First North Growth Market | 331 | GlobeNewswire | Asarina Pharma AB (publ) has applied for its shares to be delisted from Nasdaq
First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to delist the
shares in Asarina... ► Artikel lesen | |
13.09.24 | Nasdaq Stockholm AB: The observation status for Asarina Pharma AB (publ) is updated | 465 | GlobeNewswire | On July 18, 2024, Asarina Pharma AB (publ) (the "Company") issued a press
release with information that the Company intends to propose that an
extraordinary general meeting resolves that the Company... ► Artikel lesen | |
13.09.24 | Asarina Pharma AB: Asarina Pharma applies for the delisting of the company's shares | 223 | GlobeNewswire (Europe) | Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on August 21, 2024 that the Company shall enter into voluntary liquidation.... ► Artikel lesen | |
ASARINA PHARMA Aktie jetzt für 0€ handeln | |||||
19.07.24 | Nasdaq Stockholm AB: Asarina Pharma AB (publ) receives observation status | 360 | GlobeNewswire | On July 18, 2024, Asarina Pharma AB (publ) (the "Company") issued a press
release with information that the Company intends to propose that an
extraordinary general meeting resolves that the Company... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 37,020 | -1,57 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,480 | -36,02 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
ADMA BIOLOGICS | 21,860 | -2,10 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 50,000 | +0,06 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | ||
TEMPUS AI | 52,90 | -1,13 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 44,740 | -0,42 % | EQS-Adhoc: Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme | EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Firmenübernahme
Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme
24.04.2025 /... ► Artikel lesen | |
EVOTEC | 7,382 | +0,52 % | Evotec: Neue Strategie und starkes Ergebnis im vierten Quartal! | ||
BIONTECH | 102,10 | -0,10 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
DYNE THERAPEUTICS | 11,060 | -0,45 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy | - Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned... ► Artikel lesen | |
HARMONY BIOSCIENCES | 29,610 | +0,61 % | JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? | ||
VERVE THERAPEUTICS | 5,760 | -0,35 % | Why Verve Therapeutics Zoomed 40% Higher This Week | ||
RECURSION PHARMACEUTICALS | 5,740 | -0,17 % | Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? | ||
VIR BIOTECHNOLOGY | 6,120 | -2,70 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data... ► Artikel lesen | |
CG ONCOLOGY | 22,400 | +4,04 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
RELAY THERAPEUTICS | 3,200 | +0,31 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival |
New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen |